ArticleEuropean archives of psychiatry and clinical neuroscience2026
Association between neuronal pentraxin 2, ADHD symptoms, and executive functioning in adults with ADHD: a case-control study.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNeuronal pentraxin 2 (NPTX2), a synaptic protein regulating AMPA receptors and glutamate homeostasis, has been suggested as a biomarker of synaptic integrity in neurodegenerative and psychiatric disorders. This study investigated plasma NPTX2 levels in adults with ADHD and their associations with symptom severity and executive functioning.
methodsIn this cross-sectional case-control study, 79 medication- and comorbidity-free adults with ADHD and 70 matched typical controls were recruited. Participants underwent structured clinical interviews, standardized self-report scales on ADHD and comorbid anxiety/depression symptoms, and neurocognitive tests (Stroop, Wisconsin Card Sorting, Cancellation, Serial Digit Learning, Judgment of Line Orientation). Plasma NPTX2 levels were measured using ELISA. Between-group comparisons, correlation analyses, and multiple regressions adjusting for demographic and comorbid symptoms were conducted.
resultsAdults with ADHD showed significantly higher NPTX2 levels than controls, with a small effect size. Within the ADHD group, higher NPTX2 was negatively correlated with ADHD symptom severity, excessive mind wandering, and poorer performance on executive function tests (Stroop, Wisconsin Card Sorting, Cancellation). These correlations were not observed in controls. Regression analyses confirmed that the association between NPTX2 and ADHD symptoms remained significant after adjusting for age, gender, education, and anxiety/depression scores.
conclusionElevated NPTX2 levels in adults with ADHD and their negative associations with symptom severity and executive dysfunction may suggest a potential compensatory neuroprotective role. NPTX2 may serve as a non-invasive biomarker reflecting synaptic processes in ADHD. Longitudinal and interventional studies are needed to clarify its temporal dynamics and clinical utility.
Indexed as
Identifiers
41489639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.